A number of firms have modified their ratings and price targets on shares of Merck KGaA (FRA: MRK) recently:

  • 9/13/2019 – Merck KGaA was given a new €110.00 ($127.91) price target on by analysts at Bank of America Corp. They now have a “neutral” rating on the stock.
  • 9/12/2019 – Merck KGaA was given a new €100.00 ($116.28) price target on by analysts at JPMorgan Chase & Co.. They now have a “neutral” rating on the stock.
  • 9/12/2019 – Merck KGaA was given a new €108.00 ($125.58) price target on by analysts at Sanford C. Bernstein. They now have a “neutral” rating on the stock.
  • 9/10/2019 – Merck KGaA was given a new €96.00 ($111.63) price target on by analysts at Morgan Stanley. They now have a “neutral” rating on the stock.
  • 9/6/2019 – Merck KGaA was given a new €110.00 ($127.91) price target on by analysts at Credit Suisse Group AG. They now have a “buy” rating on the stock.
  • 8/15/2019 – Merck KGaA was given a new €96.00 ($111.63) price target on by analysts at HSBC Holdings plc. They now have a “neutral” rating on the stock.
  • 8/14/2019 – Merck KGaA was given a new €82.00 ($95.35) price target on by analysts at Barclays PLC. They now have a “sell” rating on the stock.
  • 8/14/2019 – Merck KGaA had its “buy” rating reaffirmed by analysts at DZ Bank AG.
  • 8/9/2019 – Merck KGaA was given a new €96.00 ($111.63) price target on by analysts at Deutsche Bank AG. They now have a “neutral” rating on the stock.
  • 8/9/2019 – Merck KGaA was given a new €108.00 ($125.58) price target on by analysts at Sanford C. Bernstein. They now have a “neutral” rating on the stock.
  • 8/9/2019 – Merck KGaA was given a new €100.00 ($116.28) price target on by analysts at JPMorgan Chase & Co.. They now have a “neutral” rating on the stock.
  • 8/9/2019 – Merck KGaA was given a new €102.00 ($118.60) price target on by analysts at Independent Research GmbH. They now have a “neutral” rating on the stock.
  • 8/9/2019 – Merck KGaA was given a new €94.00 ($109.30) price target on by analysts at Nord/LB. They now have a “neutral” rating on the stock.
  • 8/8/2019 – Merck KGaA was given a new €99.00 ($115.12) price target on by analysts at UBS Group AG. They now have a “neutral” rating on the stock.
  • 8/8/2019 – Merck KGaA was given a new €110.00 ($127.91) price target on by analysts at Credit Suisse Group AG. They now have a “buy” rating on the stock.
  • 7/30/2019 – Merck KGaA was given a new €103.00 ($119.77) price target on by analysts at Warburg Research. They now have a “neutral” rating on the stock.
  • 7/23/2019 – Merck KGaA had its “buy” rating reaffirmed by analysts at DZ Bank AG.

FRA MRK traded up €1.66 ($1.93) on Friday, reaching €99.02 ($115.14). The company had a trading volume of 739,433 shares. Merck KGaA has a 52-week low of €76.60 ($89.07) and a 52-week high of €115.00 ($133.72). The company’s fifty day moving average is €94.83 and its 200 day moving average is €94.65.

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Story: Cost of Capital Explained

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.